Gossamer Bio Q3 net loss per share narrows 57% year over year to $7.36
GOSS•Gossamer Bio’s third-quarter 2026 net loss narrowed to $48.07 million, while revenue more than doubled to $38.43 million, primarily due to revenue recognized upon termination of its Chiesi collaboration.
1. Quarterly results
Gossamer Bio’s third-quarter 2026 net loss narrowed year over year to $48.07 million. Revenue more than doubled to $38.43 million, primarily due to revenue recognized upon termination of the Chiesi collaboration. Research and development expenses fell 59% to $18.83 million, primarily driven by lower seralutinib clinical-trial costs.
2. Seralutinib plans
The first seralutinib NDA was submitted in September 2026 for pulmonary arterial hypertension, and a potential commercial launch is planned for 2027. FDA acceptance of the NDA in 2026 could unlock approximately $125 million in additional private-placement proceeds, subject to customary closing conditions.
